| Name | Title | Contact Details |
|---|
The Mighty is a digital health community created to empower and connect people facing health challenges and disabilities. We have over 2.5 million registered users and are adding a new one every 20 seconds. Our stories and videos are viewed and shared more than 90 million times a month. But those are just stats. This experience from a community member is what we`re really after: “How is it that I read an essay on The Mighty and it is the only place in the world where I feel truly understood? Time and time again you speak to me through your contributors. I read this headline and it could have come from my very lips…I wanted to say thank you – words can never express how truly grateful I am to the author for sharing her story, for all Mighty contributors, and to The Mighty itself. You have changed my life. I have made a close friend who lives many miles away because of our shared pain. I gain insight everyday and I finally, finally do not feel so alone in this world. Thank you. Bless you!”
The Top Fitness Boot Camp Known To Flatten Your Stomach & Tone Your Entire Body In A Safe, Fun And Non-Intimidating Atmosphere! 90% OFF 5 Week Challenge
ProCare Rx is a Duluth, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
AcelRx Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. The Company`s product candidates, DSUVIA™ (known as ARX-04 outside of the United States) and ZALVISO®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. DSUVIA is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. The Phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. In clinical studies, DSUVIA demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and vomiting. A New Drug Application (NDA) was filed with the FDA in December 2016. ZALVISO is designed to deliver sublingual tablets containing 15 mcg sufentanil via a novel hand-held, pre-programmed, patient-controlled analgesia system. Three Phase 3 clinical trials have been completed in patients who had undergone major abdominal or orthopedic surgeries. A fourth study (IAP312) is underway to further evaluate the overall performance of the ZALVISO System in post-surgical patients. ZALVISO is currently approved by the European Commission for the management of acute moderate-to-severe post-operative pain in adult patients in a hospital setting, and is marketed by Grünenthal Group, AcelRx`s licensee in Europe and Australia. In the United States and other geographies, ZALVISO remains an investigational product.
Edgerton Hospital and Health Services is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Edgerton, WI. To find more information about Edgerton Hospital and Health Services, please visit www.edgertonhospital.com